FDA Leadership & Vaccine Policy
Trump Nominates Heidi Overton as FDA Chief Amid Vaccine Policy Push and Agency Scrutiny
Key Points
Overton accompanied President Trump at the Oval Office signing of an executive order to pare back the childhood vaccine schedule and tied immunization to autism, a claim scientists say is unfounded.
The FDA has been led by acting chief Kyle Diamantas since May, following the resignation of commissioner Marty Makary amid White House pressure and scrutiny over the agency’s decisions.
Overton is a physician by training who previously worked in the first Trump White House and later led the health policy center at the America First Policy Institute.
Bloomberg News first reported the nomination; the move signals alignment between FDA leadership and the White House’s broader health-policy priorities, including ongoing vaccine policy changes.
President Trump plans to nominate Heidi Overton, a top White House health aide, to lead the Food and Drug Administration, The Wall Street Journal reported. Overton currently serves as a deputy director of the Domestic Policy Council, where she has been one of the key architects of the administration's health agenda.
The pick comes after months of turmoil at the FDA. The agency has been run by acting chief Kyle Diamantas since May, when former commissioner Marty Makary resigned amid White House pressure over the agency's regulatory decisions, according to McClatchy.
FDA Has Been Rudderless for Months
The FDA's leadership crisis began when Marty Makary stepped down under pressure from White House health advisers. High-profile staff exits followed. Kyle Diamantas has held the acting chief role since then, leaving the agency without a confirmed leader for months, McClatchy reported.
The agency has faced internal clashes and outside scrutiny over its handling of drug approvals and vaccine policy. The instability created urgency for the White House to install permanent leadership aligned with its health priorities, according to The Star-Telegram.
Overton Helped Drive Vaccine Policy Changes
Overton stood in the Oval Office as Trump signed an executive order to scale back the childhood vaccination schedule. The order also linked immunization to autism — a claim scientists have repeatedly debunked. Her visible role at that signing signaled her influence over the administration's health direction, according to Myrtle Beach Online.
The childhood vaccine schedule sets which shots children receive and when. Changing it is a major step with broad public health implications. Overton's involvement in shaping that policy shows where her priorities align with the White House's broader "Make America Healthy Again" push.
A Physician Insider With Deep Policy Roots
Overton is a physician by training. She worked in the first Trump White House before leaving to lead the health policy center at the America First Policy Institute, a conservative think tank closely tied to the Trump orbit, The Wall Street Journal reported.
That background sets her apart from some past FDA nominees. She brings both medical credentials and years of experience shaping policy from inside the administration. Supporters argue that makes her well-suited to align the FDA with the White House's health agenda without a steep learning curve.
Bloomberg First Broke the News, Confirmation Awaits
Bloomberg News first reported the planned nomination. Tri-City Herald and other outlets quickly confirmed the story. Overton still requires Senate confirmation before she can officially take over the FDA, which oversees the safety of food, drugs, medical devices, and vaccines used by millions of Americans.
If confirmed, she would take over an agency navigating a wave of regulatory and staffing challenges. Her close ties to Trump advisers — including Robert F. Kennedy Jr.'s health team — suggest the FDA's direction under her leadership would tilt sharply toward the White House's current health priorities, according to The Star-Telegram.
Sentiment
Mostly NegativePublishers
15
Articles
156
Reach
171
